|
| 34822201 | Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients. | Am J Hematol | 2022 |
| 36051067 | Transcriptional profiles define drug refractory disease in myeloma. | | 2022 |
| 32503975 | Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity. | Leukemia | 2020 |
| 31582538 | Identification of PIKfyve kinase as a target in multiple myeloma. | Haematologica | 2020 |
| 32393731 | Direct to Drug screening as a precision medicine tool in multiple myeloma. | Blood Cancer Journal | 2020 |
| 29381435 | Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. | J Clin Oncol | 2018 |
| 29623394 | Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. | Annals of Hematology | 2018 |
| 29563506 | A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. | Blood Cancer J | 2018 |
| 28028022 | Multiple myeloma cells' capacity to decompose H<sub>2</sub>O<sub>2</sub> determines lenalidomide sensitivity. | Blood | 2017 |
| 27730341 | Prevalence of BCL-2/J(H) Translocation in Healthy African Americans. | Ann Hematol | 2017 |
| 27841872 | IAP antagonists induce anti-tumor immunity in multiple myeloma. | Nat Med | 2016 |
| 26918361 | Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. | Blood Cancer Journal | 2016 |
| 27071340 | Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. | Br J Haematol | 2016 |
| 26202926 | Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. | Leukemia | 2016 |
| 26164366 | Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. | Oncotarget | 2015 |
| 25743686 | Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). | Annals of Hematology | 2015 |
| 25302557 | Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. | British Journal of Haematology | 2015 |
| 24129344 | The clinical significance of cereblon expression in multiple myeloma. | Leukemia Research | 2014 |
| 24451410 | BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. | Leukemia | 2014 |
| 24505276 | Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements. | PLoS One | 2014 |
| 23716545 | Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. | Haematologica | 2013 |
| 23422747 | Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. | Blood | 2013 |
| 21860025 | Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. | Blood | 2011 |
| 21430775 | Initial genome sequencing and analysis of multiple myeloma. | Nature | 2011 |
| 21902684 | Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. | British Journal of Haematology | 2011 |
| 20736376 | DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. | Cancer Research | 2010 |
| 19805681 | Spontaneous remission in a patient with t(4;14) translocation multiple myeloma. | J Clin Oncol | 2009 |
| 18567838 | Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. | Blood | 2008 |
| 18349285 | Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility. | Cancer Epidemiology Biomarkers and Prevention | 2008 |
| 16840723 | Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. | Blood | 2007 |
| 17409404 | Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. | Cancer Research | 2007 |
| 17692805 | Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. | Cancer Cell | 2007 |
| 17568814 | Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. | Leukemia | 2007 |
| 16938573 | 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. | Cancer Genetics and Cytogenetics | 2006 |
| 16111750 | Ploidy status rarely changes in myeloma patients at disease progression. | Leukemia Research | 2006 |
| 16373658 | Clinical implication of centrosome amplification in plasma cell neoplasm. | Blood | 2006 |
| 17024118 | Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. | Leukemia | 2006 |
| 16511510 | Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. | Leukemia | 2006 |
| 15920009 | A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. | Blood | 2005 |
| 15976175 | Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. | Blood | 2005 |
| 14726402 | Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. | Blood | 2004 |
| 12710218 | Assays for neoplastic cell enrichment in bone marrow samples. | Methods in molecular medicine | 2003 |
| 12351413 | Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. | Blood | 2002 |
| 12149226 | Genomic abnormalities in monoclonal gammopathy of undetermined significance. | Blood | 2002 |
| 11801310 | Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. | Cancer Genetics and Cytogenetics | 2002 |
| 11567982 | Systemic therapy of myeloma xenografts by an attenuated measles virus. | Blood | 2001 |
| 11568015 | Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. | Blood | 2001 |
| 11342320 | Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis. | Leukemia and Lymphoma | 2000 |
| 10609798 | Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. | Leukemia and Lymphoma | 1999 |
| 9864174 | Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. | Blood | 1999 |